BioCentury
ARTICLE | Company News

Vidara Therapeutics, Horizon Pharma deal

September 29, 2014 7:00 AM UTC

Specialty pharma Horizon Pharma completed its acquisition of Vidara through a reverse merger in a cash and stock deal that Horizon said values Vidara at about $660 million (see BioCentury, March 24). ...